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Instructor:
Office:
Phone:
E-Mail Address:
Office Hours:

Class Meets:

Syllabus: BIOS 9132 – Advanced Clinical Trial Methodology
Jiann-Ping Hsu College of Public Health
Georgia Southern University
Hendricks Hall, PO Box 8015
Statesboro, GA 30460
Fall Term, 2017
Karl E. Peace
1005 Hendricks Hall
912-478-7905
kepeace@georgiasouthern.edu
peacekarl@frontier.com
Wednesday– 3:00 PM – 5:00 PM
Other times by appointment:
Students are encouraged to make frequent use of email contact where each
question will be responded via return email
Wednesday – 5:00 AM-to-7:45 PM Fall Semester

Prerequisites:

Clinical Trial Methodology or Statistical Issues in Drug Research and
Development, or by permission of instructor.

Catalog Description:

Students are introduced to regulatory, scientific, statistical and
practical aspects of methods inherent in design, monitoring and
analyzing clinical trials. Clinical trials in many areas of drug
development are presented, discussed and critiqued.

No textbook required – although the text: Peace, K. E., Chen, D
(2010): Clinical Trial Methodology; Chapman & Hall/CRC, Taylor and Francis
Group, will be very helpful. The course is presented using power points developed by

Required Textbook:

the professor. Students are provided copies of the power points on a flash drive.

Secondary Texts:
Peace, K. E., Chen, D (2010): Clinical Trial Methodology; Chapman & Hall/CRC, Taylor
and Francis Group.
Chen D, Peace KE (2010): Clinical Trial Data Analysis using R; Chapman & Hall/CRC,
Taylor and Francis Group; ISBN: 978-1-4398-4020-7
Chen, D, Peace KE (2013): Applied Meta-Analysis using R. Chapman & Hall/CRC,
Taylor and Francis Group; 13: 978-1-4665-0599-5; May, 2013.
Chen D, Sun J, Peace KE [Editors and Author contributors] (2012): Interval-Censored
Time-to-Event Data: Methods and Applications"; Chapman & Hall/CRC, Taylor and
Francis Group; Published July, 2012.
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Peace, K. E. [Editor and Author contributor] (2008): Design and Analysis of Clinical
Trials with Time to Event Endpoints; Chapman & Hall/CRC Taylor and Francis
Group; Boca, ISBN 978-1-4200-6639-5.
Peace, K. E. [Editor and Author contributor] (1992): Biopharmaceutical Sequential
Statistical Applications. Marcel Dekker, Inc., New York, ISBN 0-8247-8628-9.
Peace, K. E. [Editor and Author contributor] (1990): Statistical Issues in Pharmaceutical
Drug Development. Marcel Dekker, Inc., New York, ISBN 0-8247-8290-9.
Peace, K.E. [Editor and author] (1988): Biopharmaceutical Statistics in Drug
Development. Marcel Dekker, Inc., New York, ISBN 0-8247-7798-0.
Biostatistics Student Learning Outcomes (BSLO):
Cross-cutting
1. Demonstrate their readiness to work with communities to address public health problems.
2. Select and apply theoretically based interventions to address public health problems.
3. Apply appropriate research methods to address community health problems, particularly
among rural and underserved populations.
Biostatistics Concentration
1. Construct a public health and biomedical research question from ideas, conditions, and
events that exist in a rural and urban community, region, state, and nation using critical
thinking skills.
2. Demonstrate required skills for translating public health practice objectives to the
appropriate biostatistical framework for analysis and interpretation of results.
3. Illustrate sufficient substantive knowledge of advanced biostatistical methods such as
multiple regression, logistic regression, survival analysis, longitudinal data analysis, and
Bayesian and adaptive methods to interact with biostatisticians and related public health
researchers in a meaningful and productive fashion.
4. Communicate biostatistical principles and concepts to lay and professional audiences
through both oral and written communication.
Course Objectives: At the end of this course, students should be able to:
1. Explain the requirements for good protocol development for biomedical research
clinical trials and develop the statistical analysis section of such protocols (BSLO:
1,2,3,4)
2. Describe methodological alternatives to commonly used statistical methods used in
biomedical research clinical trials when analysis assumptions are not met, and
describe prerequisites for validity of inference from clinical trials (BSLO: 1,2,3,4)
3. Interpret results of statistical analyses of data collected from biomedical clinical trials
(BSLO: 3,4)
4. Develop written and oral presentations based on statistical analyses of biomedical
research clinical trials, for both biomedical research professionals and educated lay
audiences (BSLO: 2,3,4)
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5. Identify key federal regulations ‘governing’ the conduct of clinical trials (BSLO:
1,2,3)
6. Discuss the Ethics of Clinical Trial Research (BSLO: 1,3,4)
7. Describe the components of Population Nonlinear, Mixed Effects Modeling (BSLO:
2,3,4)
8. Design, analyze and interpret results of bioequivalence, cancer and non-inferiority
clinical trials (BSLO: 1,2,3,4)
9. Describe the issues in group sequential clinical trials and in subset analyses (BSLO:
1,2,3,4)
10. Describe ‘intention to treat’ and its impact on inference when data are missing and
methods of imputing missing data (BSLO: 1,2,3,4)
Advanced Clinical Trial Methodology Content to be Covered During the Semester:
Module I: An Overview of the Regulation of Pharmaceuticals
Module II: An Overview of the Processes of Discovery, Basic Research, Clinical Development
and Manufacturing in Pharmaceutical Development
Module IIII: Ethics of Clinical Trial Research
Module IV: Overview of Biostatistical Aspects of Clinical Drug Development
A. The Components of a Protocol
B. Statistical Analysis Section of a Clinical Trial Protocol
C. The Statistical Analysis Plan
Module V: Statistical Analysis Plan
Module VI: Validity of Statistical Inference
Module VII: Population Nonlinear, Mixed Effects Modeling of Primary Efficacy Endpoint in
Enrichment Trials of Alzheimer’s disease
Module VIII: Biostatistical Aspects of the Design of Cancer Trials
Module IX: Biostatistical Aspects of the Analysis and Interpretation of Cancer Clinical Trials
Module X: Interim Analyses: p-Value and Power Computations in Group Sequential Trials
Module XI: Statistical Analysis of Dose Response Trials
Module XII: Safety Assessment in Clinical Trials
Module XIII: Subgroup Analyses in Clinical Trials from a Causal Inference Viewpoint
Module XIV: Statistical Paradigms and Methodologies for Clinical Development
Module XV: Biosimilarity
Module XVI: A Clinical Trial to Reduce CHD Risk
Module XVII: Intention-to-Treat and Inferential Impact of Missing Data
Module XVIII: Methods for Imputing Missing Data
Module XIX: Overview of Meta-Analyses
Module XX: Design and Analysis of Non-inferiority Clinical trials
Module XXI: Sample size of clinical trials premarket approval
Module XXII: Numbers Needed to Treat in Clinical trials
Instructional Methods: Class meetings will be a combination of lecture and class discussion.
Approximately half of the class meetings will be facilitated via Adobe Connect or Cisco Webex
in real time (blended format) and the remainder physically in the classroom. Homework
assignments – including a research project that requires class presentation and the final
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examination constitute the basis of student evaluation. Students are expected to make use of
ample office hours to discuss concepts or difficulties they may have. Office hours may be
individualized via using Adobe Connect or Cisco Webex or in professor’s office.
Daily Study Log: Students are required to keep a daily computerized study log. The study log
should have a column for the date, a column to identify topic of study, a column to identify the
time of beginning study, a column to identify the ending time of study, and a column to identify
the amount of time spent in studying the topic. This allows students to provide greater input to
the professor as to time spent studying during the semester.
Grading: Weighting of assignments for purposes of grading will be as follows:
Final Exam (objectives 1-14, integrated)………………………………………...60%
Homework & Research Project Assignments (objectives 1-14, individually)…..30%
Class Participation (objectives 1-14, individually)………………………………10%
____
Total Possible
100%
The following point scale will be utilized in grading:
90% - 100%
80% - 90%
70% - 80%
60% - 70%

A
B
C
D

There are times when extraordinary circumstances occur (e.g., serious illness, death in the
family, etc.). In such circumstances, and/or if you need additional time to satisfactorily complete
any course requirement, please consult with the instructor within a reasonable amount of time.
Academic Misconduct: As a student registered at this University, it is expected that you will
adhere to only the strictest standards of conduct. Your continued enrollment in this course is an
implied contract between you and the instructor on this issue; from this point forward, it is
assumed that you will conduct yourself appropriately.
Academic integrity relates to the appropriate use of intellectual property. The syllabus, lecture
notes, and all materials presented and/or distributed during this course are protected by copyright
law. Students are authorized to take notes in class, but that authorization extends only to making
one set of notes for personal (and no other) use. As such, students are not authorized to sell,
license, commercially publish, distribute, transmit, display, or record notes in or from class
without the express written permission of the instructor.
Plagiarism: Plagiarism includes (but is not limited to): A. Directly quoting the words of others
without using quotation marks or indented format to identify them. B. Using published or
unpublished sources of information without identifying them. C. Paraphrasing material or ideas
without identifying the source. D. Unacknowledged use of materials prepared by another person
or agency engaged in the selling of term papers or other academic material.
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Attendance Policy: Federal regulations require attendance be verified prior to distribution of
financial aid allotments. Students are expected to attend all classes, whether taking for credit or
auditing (Instructor will permit missing 1-2 classes for valid reasons).
One Final Note: The contents of this syllabus are as complete and accurate as possible. The
instructor reserves the right to make any changes necessary to the syllabus and course material.
The instructor will make every effort to inform students of changes as they occur. It is the
responsibility of the student to know what changes have been made in order to successfully
complete the requirements of the course.
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Student Information (ADV CTM Class):
Print Full Name

email address

Pledge to spend enough time
to master material? Circle one.

1. ________________

________________

Yes

No

Undecided

2. ________________

________________

Yes

No

Undecided

3. ________________

________________

Yes

No

Undecided

4. ________________

________________

Yes

No

Undecided

5. ________________

________________

Yes

No

Undecided

6. ________________

________________

Yes

No

Undecided

7. ________________

________________

Yes

No

Undecided

8. ________________

________________

Yes

No

Undecided

9. ________________

________________

Yes

No

Undecided

Yes

No

Undecided

10. ________________

________________
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